NICE Clears Cosentyx For Psoriasis And Moventig For Constipation
This article was originally published in The Pink Sheet Daily
Final draft guidance recommends Novartis’s IL-17 inhibitor for use in Britain’s National Health Service if supplied at a discounted price, and AstraZeneca’s peglyated naloxol product.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Germany’s Merck KGaA rapidly expanded its life sciences services business to support the manufacture of COVID-19 vaccines during 2020, and also expects cancer and multiple sclerosis products to fuel its sales growth in coming years.
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.